Therapeutic efficacy of intra‑tumor AvidinOX and low systemic dose biotinylated cetuximab, with and without cisplatin, in an orthotopic model of head and neck cancer

Vesci,Loredana; Carollo,Valeria; Rosi,Antonio; De Santis,Rita

doi:10.3892/ol.2019.10003

Therapeutic efficacy of intra‑tumor AvidinOX and low systemic dose biotinylated cetuximab, with and without cisplatin, in an orthotopic model of head and neck cancer

Authors:
- Loredana Vesci
- Valeria Carollo
- Antonio Rosi
- Rita De Santis
View Affiliations

Affiliations: Biotechnology R&D, Alfasigma S.p.A., Pomezia, I‑00071 Rome, Italy, Histo‑Cyto Service, I‑00151 Rome, Italy
Published online on: February 1, 2019 https://doi.org/10.3892/ol.2019.10003
Pages: 3529-3536

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In a previous study, the efficacy of low intraperitoneal doses of biotinylated cetuximab (bCet) in mice with subcutaneous tumor xenografts of human head and neck cancer (HNC) treated intra‑tumors with AvidinOX was reported. Taking into account that the current standard treatment for HNC is the combination of cetuximab and cisplatin, the present study investigated the activity of AvidinOX‑targeted bCet with and without cisplatin in an orthotopic model. The results confirmed that administration of intra‑tumor AvidinOX makes an otherwise inactive dose of bCet effective in reducing tumor growth, and the addition of a low dose of cisplatin further improved tumor growth inhibition. Supporting the in vivo data, immunohistochemical staining of tumor masses from mice treated with AvidinOX, bCet and cisplatin exhibited the highest tumor cell damage and the lowest angiogenic activity among all treatment groups, measured as the number of γ-H2A.X and cleaved caspase‑3‑positive cells, and vascular endothelial growth factor‑C and platelet and endothelial cell adhesion molecule 1‑positive cells, respectively. AvidinOX is currently under clinical investigation to assess its use in delivering radioactive biotin to inoperable tumor lesions (ClinicalTrials.gov: NCT02053324 and NCT03188328). The present study further supported the potential clinical use of AvidinOX to target low bCet doses to inoperable tumor lesions, with or without an additional low dose of cisplatin. Since low doses of highly expensive monoclonal antibodies become effective with AvidinOX and low dose cisplatin, such therapies promise to be cheaper and less toxic than current treatments.

View Figures

View References

1	De Felice F, Polimeni A, Valentini V, Brugnoletti O, Cassoni A, Greco A, De Vincentiis M and Tombolini V: Radiotherapy controversies and prospective in head and neck cancer: A literature-based critical review. Neoplasia. 20:227–232. 2018. View Article : Google Scholar : PubMed/NCBI
2	Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, et al: Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): An open-label phase 3 randomised trial. Lancet Oncol. 14:697–710. 2013. View Article : Google Scholar : PubMed/NCBI
3	Vermorken JB, Licitra L, Stöhlmacher-Williams J, Dietz A, Lopez-Picazo JM, Hamid O, Hamid O, Hossain AM, Chang SC and Gauler TC: Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 49:2877–2883. 2013. View Article : Google Scholar : PubMed/NCBI
4	Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, et al: Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 32:2940–2950. 2014. View Article : Google Scholar : PubMed/NCBI
5	Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, Yunus F, Kurland BF, Eaton KD, Liao JJ, et al: Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized phase II trial. J Clin Oncol. 31:1415–1421. 2013. View Article : Google Scholar : PubMed/NCBI
6	Numico G, Franco P, Cristofano A, Migliaccio F, Spinazzé S, Silvestris N, Cante D, Sciacero P, La Porta MR, Girelli F and Ricardi U: Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. Crit Rev Oncol Hematol. 85:112–120. 2013. View Article : Google Scholar : PubMed/NCBI
7	De Santis R, Albertoni C, Rosi A, Leoni B, Petronzelli F, D'Alessio V, Nucera E, Salvatori G, Paganelli G, Verdoliva A, et al: OXavidin for tissue targeting biotinylated therapeutics. J Biomed Biotechnol. 2009:9214342009. View Article : Google Scholar : PubMed/NCBI
8	De Santis R, Leoni B, Rosi A, Albertoni C, Forni G, Cojoca R, Iezzi M, Musiani P, Paganelli G, Chinol M and Carminati P: AvidinOX for highly efficient tissue-pretargeted radionuclide therapy. Cancer Biother Radiopharm. 25:143–148. 2010. View Article : Google Scholar : PubMed/NCBI
9	De Santis R, Anastasi AM, Pelliccia A, Rosi A, Albertoni C, Verdoliva A, Petronzelli F, D'Alessio V, Serani S and Nuzzolo CA: Chemical linkage to injected tissues is a distinctive property of oxidized avidin. PLoS One. 6:e210752011. View Article : Google Scholar : PubMed/NCBI
10	Nucera E, Nicoletti C, Chiapparino C, Pacello ML, D'Alessio V, Musarò A and De Santis R: AvidinOX™ for tissue targeted delivery of biotinylated cells. Int J Immunopathol Pharmacol. 25:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
11	Verdoliva A, Bellofiore P, Rivieccio V, Catello S, Colombo M, Albertoni C, Rosi A, Leoni B, Anastasi AM and De Santis R: Biochemical and biological characterization of a new oxidized avidin with enhanced tissue binding properties. J Biol Chem. 285:9090–9099. 2010. View Article : Google Scholar : PubMed/NCBI
12	Albertoni C, Leoni B, Rosi A, D'Alessio V, Carollo V, Spagnoli LG, van Echteld C and De Santis R: Radionuclide therapy of unresectable tumors with AvidinOX and (90) Y-biotinDOTA: Tongue cancer paradigm. Cancer Biother Radiopharm. 30:291–298. 2015. View Article : Google Scholar : PubMed/NCBI
13	Vesci L, Milazzo FM, Anastasi AM, Petronzelli F, Chiapparino C, Carollo V, Roscilli G, Marra E, Luberto L, Aurisicchio L, et al: Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer. Oncotarget. 7:914–928. 2016. View Article : Google Scholar : PubMed/NCBI
14	Urbano N, Papi S, Ginanneschi M, De Santis R, Pace S, Lindstedt R, Ferrari L, Choi S, Paganelli G and Chinol M: Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT). Eur J Nucl Med Mol Imaging. 34:68–77. 2007. View Article : Google Scholar : PubMed/NCBI
15	Kilkenny C, Browne WJ, Cuthill JC, Emerson M and Altman DG: Improving bioscence research reporting: The ARRIVE guidelines for reporting animal research. Osteoarthritis Cartilage. 20:256–260. 2012. View Article : Google Scholar : PubMed/NCBI
16	Massi D, Puig S, Franchi A, Malvehy J, Vidal-Sicart S, González-Cao M, Baroni G, Ketabchi S, Palou J and Santucci M: Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: A case-control study. J Clin Pathol. 59:166–173. 2006. View Article : Google Scholar : PubMed/NCBI
17	Schneider CA, Rasband WS and Eliceiri KW: NIH image to imageJ: 25 years of image analysis. Nat Methods. 9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
18	Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M and Zunino F: In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol. 41:385–390. 1998. View Article : Google Scholar : PubMed/NCBI
19	De Santis R, Rosi A, Anastasi AM, Chiapparino C, Albertoni C, Leoni B, Pelliccia A, Santapaola D, Carollo V, Marra E, et al: Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab. Oncotarget. 5:9239–9255. 2014. View Article : Google Scholar : PubMed/NCBI
20	Milazzo FM, Anastasi AM, Chiapparino C, Rosi A, Leoni B, Vesci L, Petronzelli F and De Santis R: AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies. Oncotarget. 8:22590–22605. 2017. View Article : Google Scholar : PubMed/NCBI
21	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
22	Basu A and Krishnamurthy S: Cellular responses to cisplatin-induced DNA damage. J Nucleic Acids. 2010(pii): 2013672010.PubMed/NCBI
23	Arimoto S, Hasegawa T, Takeda D, Saito I, Amano R, Akashi M and Komori T: Lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma. Anticancer Res. 38:6157–6162. 2018. View Article : Google Scholar : PubMed/NCBI
24	Lonser RR, Sarntinoranont M, Morrison PF and Oldfield EH: Convection-enhanced delivery to the central nervous system. J Neurosurg. 122:697–706. 2015. View Article : Google Scholar : PubMed/NCBI
25	Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, Garden AS, Shenouda G, Harris J and Ang KK: Final results of local-regional control and late toxicity of RTOG 9003: A randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 89:13–20. 2014. View Article : Google Scholar : PubMed/NCBI
26	Kfoury M, Disdero V, Vicier C, Le Saux O, Gougis P, Sajous C and Vignot S: Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives. Bull Cancer. 105:686–695. 2018.(In French). View Article : Google Scholar : PubMed/NCBI
27	Yoneda K, Imanishi N, Ichiki Y and Tanaka F: Immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). J UOEH. 40:173–189. 2018. View Article : Google Scholar : PubMed/NCBI
28	Durante M and Formenti SC: Radiation-induced chromosomal aberrations and immunotherapy: Micronuclei, cytosolic DNA, and interferon-production pathway. Front Oncol. 8:1922018. View Article : Google Scholar : PubMed/NCBI
29	Ni K, Lan G, Chan C, Quigley B, Lu K, Aung T, Guo B, La Riviere P, Weichselbaum RR and Lin W: Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun. 9:23512018. View Article : Google Scholar : PubMed/NCBI